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ABSTRACT
OBJECTIVES The aim of this study was to investigate whether therapeutic intravascular ultrasound pulmonary artery
denervation (PDN) is safe and reduces pulmonary vascular resistance (PVR) in patients with pulmonary arterial
hypertension (PAH) on a minimum of dual oral therapy.
BACKGROUND Early studies have suggested that PDN can reduce PVR in patients with PAH.
METHODS TROPHY1 (Treatment of Pulmonary Hypertension 1) was a multicenter, international, open-label trial
undertaken at 8 specialist centers. Patients 18 to 75 years of age with PAH were eligible if taking dual oral or triple
nonparenteral therapy and not responsive to acute vasodilator testing. Eligible patients underwent PDN (TIVUS System).
The primary safety endpoint was procedure-related adverse events at 30 days. Secondary endpoints included procedure-
related adverse events, disease worsening and death to 12 months, and efficacy endpoints that included change in
pulmonary hemodynamic status, 6-min walk distance, and quality of life from baseline to 4 or 6 months. Patients were to
remain on disease-specific medication for the duration of the study.
RESULTS Twenty-three patients underwent PDN, with no procedure-related serious adverse events reported. The
reduction in PVR at 4- or 6-month follow-up was 94  151 dyn$s$cm5 (p ¼ 0.001) or 17.8%, which was associated with
a 42  63 m (p ¼ 0.02) increase in 6-min walk distance and a 671  1,555 step (p ¼ 0.04) increase in daily activity.
CONCLUSIONS In this multicenter early feasibility study, PDN with an intravascular ultrasound catheter was performed
without procedure-related adverse events and was associated with a reduction in PVR and increases in 6-min walk distance
and daily activity in patients with PAH on background dual or triple therapy. (J Am Coll Cardiol Intv 2020;13:989–99)
© 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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P
atients with pulmonary arterial hy-
pertension (PAH) manifest signs of
sympathetic overdrive (1) that are
associated with poor outcomes (2). The lungs
are a major source of catecholamines and
both release and metabolize >40% of circu-
lating levels (3). It is unknown whether acti-
vation of the sympathetic nervous system is
a secondary phenomenon or whether it may play an
exacerbating and/or pathogenic role in the progres-
sion of disease. In experimental models of pulmonary
hypertension, therapies that target the sympathetic
(4,5) and renin-angiotensin-aldosterone (6) systems
reduce small-vessel remodeling and improve hemo-
dynamic status. However, in patients with PAH, the
few studies undertaken thus far have demonstrated
modulation of both pulmonary and systemic hemody-
namic status, with no evidence of clinical benefit
(7–9). Furthermore, beta-adrenergic blockade may
produce deterioration in patients with PAH resulting
from the systemic hemodynamic effects (hypoten-
sion, reduced heart rate, and cardiac output).
Catheter-based renal denervation in patients with
systemic hypertension reduces blood pressure
(10–12). Such technologies offer the opportunity to
modulate sympathetic activity through targeted
denervation of the pulmonary vasculature, poten-
tially avoiding the adverse effects of systemically
active therapies. Nerves surrounding the pulmonary
vasculature are present to a depth of 4 mm in large
animals (13,14) and 10 mm in human samples (15). In
patients with PAH, the application of radiofrequency
energy to a specific location at the bifurcation is re-
ported to provide an acute improvement in hemo-
dynamic status that persists to 3 months despite the
withdrawal of disease-specific therapy (16). Current
guidelines indicate that patients with PAH and
high-risk indicators should be treated with 2 disease-
specific therapies (17). As such, the effect of pulmo-
nary artery denervation (PDN) in patients on best
medical therapy is unknown, as is the feasibility of
ultrasound energy delivery for PDN.
The TIVUS System (SoniVie, Rosh Haayin, Israel) is
a percutaneous, noncontact catheter that provides a
fenestrated ring of thermal effect to a depth of 10 mm,
which is the expected location of the efferent and
afferent autonomic nerves in the pulmonary artery
adventitia (15). We designed this preliminary study to
investigate for the first time the feasibility of thera-
peutic intravascular ultrasound PDN, to monitor early
safety, and to determine whether the procedure
would lower pulmonary vascular resistance (PVR) in
patients with PAH established on a minimum of dual
oral therapy.
METHODS
STUDY DESIGN AND PARTICIPANTS. TROPHY1 (Treat-
ment of Pulmonary Hypertension 1) was amulticenter,
open-label, early feasibility study. Participants were
recruited from 5 hospitals in Europe and Israel and 3 in
the United States. The study was undertaken in
accordance with the Declaration of Helsinki and was
approved by local ethics committees or Institutional
Review Boards. All participants provided written
informed consent. Briefly, eligible patients were men
or women 18 to 75 years of age with PAH that did not
respond to vasodilator testing, on a minimum of dual
oral disease-specific therapy (17), with estimated
glomerular filtration rate $30 ml/min/1.73 m2.
PROCEDURES. After qualifying hemodynamic eval-
uation and pulmonary angiography, patients under-
went immediate therapeutic intravascular ultrasound
PDN (TIVUS System). A maximum of 18 activations
were delivered to nonoverlapping segments of the
main (n ¼ 8), right (n ¼ 8), and left (n ¼ 2) pulmonary
arteries. The number of activations and distance from
the pulmonary artery bifurcation was limited on the
left by the recurrent laryngeal nerve (15). Continuous
monitoring of energy output, vessel wall distance,
and temperature was used to optimize each activa-
tion, with automated safety cut-outs. Patients were
sedated and received pain-controlling medication at
the discretion of the responsible physician. The target
activated coagulation time of >250 s was achieved
with intravenous heparin to prevent coagulum
buildup on the ultrasound probe.
Post-procedural follow-up was at 1 month, 4 or
6 months (Europe and Israel, 4 months; United States,
6 months; mean 4.8  1.3 months), 8 months, and
12 months. Systemic blood pressure and heart
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rate, adverse events, 6-min walk distance, and med-
ications were recorded and laboratory assessments
undertaken at each visit. Right heart catheterization
was performed at baseline and 4- or 6-month and 12-
month follow-up in the supine position, with pul-
monary pressure and flow measurements repeated in
triplicate. Magnetic resonance imaging or computed
tomography was performed at 1 and 6 or 12 months.
Wrist-based activity monitoring was undertaken for
14 days (ActiGraph GT9X Link, ActiGraph, Pensacola,
Florida) prior to baseline, 4- or 6-month, 8-month,
and 12-month visits.
OUTCOMES. The primary endpoint was procedure-
related adverse events at 30 days (pulmonary artery
perforation, dissection, aneurysm, or stenosis; he-
moptysis; and disease- or procedure-related death).
Secondary endpoints included PAH worsening and
death to 12 months and change from baseline to 4- or
6-month follow-up in PVR, mean pulmonary artery
pressure, right atrial pressure, 6-min walk distance,
quality of life (emPHasis-10), N-terminal pro–brain
natriuretic peptide, disease-specific medication, and
actigraphy. The time-to-event endpoint was a com-
posite of death, disease-related hospitalization,
FIGURE 1 Consolidated Standards of Reporting Trials Diagram
Hemodynamic and anatomic eligibility assessment was undertaken in 24 patients. One was excluded at right heart catheterization, and 23
underwent ultrasound pulmonary artery denervation. All patients were included in adverse event (AE), serious AE (SAE), and time to clinical
worsening (TTCW) analysis. Twenty patients underwent invasive assessment of hemodynamic status at 4 or 6 months, with 3 excluded
(1 receiving intravenous [i.v.] prostanoid therapy, 1 who died, and 1 with nonadherence to therapy).
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initiation of parenteral prostanoid therapy, lung
transplantation, or atrial septostomy, whichever
occurred first, to 12 months (18). Risk assessment was
undertaken using the French invasive score with low-
risk criteria defined as World Health Organization
functional class I or II, 6-min walk distance >440 m,
right atrial pressure <8 mm Hg, and cardiac
index $2.5 l/min/m2 (19). An independent data and
safety monitoring board reviewed all potential
procedure-related serious adverse events and
adverse events.
BLINDED DATA ANALYSIS. Hemodynamic data were
analyzed blinded to participant and time point by
an independent core laboratory (Cardiovascular
Research Foundation, New York, New York).
STATISTICAL ANALYSIS. Statistical analyses were
performed using 1-way analysis of variance, the Wil-
coxon matched-pairs signed rank test, Student’s
paired t-test, and the chi-square test as appropriate in
accordance with the pre-specified statistical analysis
plan. Reported adverse events are of all patients
enrolled, but patients who did not undergo follow-up
right heart catheterization were excluded in the
reporting of hemodynamic and functional endpoints
(Figure 1). Expected survival was modeled from 6-min
walk distance, sex, and cardiac output using the
French registry equation (20).
The study is registered at ClinicalTrials.gov
(NCT02516722, NCT02835950).
FUNDING. The study was funded by SoniVie. The
advisory committee and sponsor designed the study.
Independent data collection and monitoring were
undertaken by site-specific contract research organi-
zations. Statistical analyses were performed by the
Cardiovascular Research Foundation. All authors had
access to data and were responsible for the decision
to submit.
RESULTS
Between March 2015 and April 2018, 24 patients with
PAH on a minimum of dual oral therapy were enrolled
in TROPHY1. After qualifying right heart catheteriza-
tion, 23 patients underwent PDN.
Baseline characteristics are shown in Table 1. The
mean age was 60.0  11.4 years, 18 patients (78%)
were women, and 19 (83%) were Caucasian. At the
time of enrollment, all patients were receiving dual
oral therapy, and 7 (30%) were also receiving an
inhaled prostanoid or oral prostacyclin agonist
(Table 2).
Patients received an average of 10.0 (minimum 7,
maximum 16) ultrasound activations, with 4.5 (range:
2 to 7), 1.9 (range: 1 to 2), and 4.0 (range: 1 to 8) in the
right, left, and main pulmonary arteries, respectively,
with all patients receiving the pre-specified minimum
(2 right, 1 left, and 2 main). The duration of the
denervation procedure was 32.0  9.8 min, with a
mean fluoroscopy time of 8.1  5.4 min.
There were no procedure-related serious adverse
events. Serious adverse events and adverse events
are shown in Table 3. No patients reported procedure-
related pain lasting longer than 2 days, and no
perforation, dissection, aneurysm, or stenosis was
identified by pulmonary angiography post-procedure
or magnetic resonance imaging or computed
tomography at 1 and 12 months. There was no
acute reduction in mean pulmonary artery pressure
TABLE 1 Baseline Characteristics of Patients Enrolled (N ¼ 23)
Age, yrs 60.0  11.4
Female 18 (78)
Race
Caucasian 19 (83)
Black 1 (4)
Hispanic 2 (9)
Middle East 1 (4)
Time from diagnosis, yrs 6.1  5.7
Type of PAH
Associated with connective tissue disease 12 (52)
Associated with drug use 3 (13)
Idiopathic 8 (35)
WHO functional class III 23 (100)
Values are mean  SD or n (%).
PAH ¼ pulmonary arterial hypertension; WHO ¼ World Health Organization.
TABLE 2 Medical Therapy of Patients at Baseline and 4- or
6-Month Follow-Up (N ¼ 20)
Disease-Specific Therapy Baseline 4 or 6 Months
ERA/PDE5 inhibitor 10 (50) 10 (50)
ERA/sGC 4 (20) 4 (20)
ERA/PDE5 inhibitor/inhaled prostacyclin 3 (15) 3 (15)
ERA/sGC/inhaled prostacyclin 2 (10) 2 (10)
ERA/sGC/oral IP agonist 1 (5) 1 (5)
Diuretic agents
None 3 (15) 3 (15)
Loop 7 (35) 6 (30)
Loop/aldosterone antagonist 7 (35) 8 (40)
Loop/aldosterone antagonist/thiazide 3 (15) 3 (15)
Values are n (%).
ERA ¼ endothelin receptor antagonist; IP ¼ prostacyclin;
PDE5 ¼ phosphodiesterase type 5; sGC ¼ soluble guanylate cyclase.
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(þ0.7  10.0 mm Hg; p ¼ NS), and no change in esti-
mated glomerular filtration rate was apparent at
1 month (6.1  27.0 ml/min/1.73 m2; p ¼ NS). Three
subjects did not undergo follow-up right heart cath-
eterization and were not included in efficacy analysis:
1 transitioned to intravenous prostanoid, 1 died (un-
related to the procedure), and 1 was nonadherent to
therapy (Figure 1). Survival at 4 or 6 and 12 months
was 96%. The French registry equation was used to
estimate expected survival on the basis of patient
data at the point of study entry; expected survival
was 93% and 87% at 6 and 12 months, respectively
(20). Disease-specific therapy was unchanged be-
tween baseline and 4- or 6-month follow-up in pa-
tients included in the efficacy analysis (Table 2).
Diuretic therapy was consistent between time points
(Table 2): furosemide equivalent 54 mg/day (range:
0 to 160 mg/day) versus 59 mg/day (range: 0 to
160 mg/day), aldosterone antagonist 15 mg/day
(range: 0 to 50 mg/day) versus 16.25 mg/day (range:
0 to 50 mg/day), and thiazide 0.5 mg/day (range: 0 to
5 mg/day) versus 0.5 mg/day (range: 0 to 5 mg/day).
At 4- or 6-month follow-up, hemodynamic and
functional endpoints improved: PVR was reduced by
94  151 dyn$s$cm5 (p ¼ 0.001), or 17.8%, and 6-min
walk distance increased by 42  63 m (p ¼ 0.02)
(Figures 2 to 4, Central Illustration, Table 4).
Improvements in mean pulmonary artery pressure
(5.1  7.4 mm Hg; p < 0.01), right atrial pressure
(2.4  3.5 mm Hg; p ¼ 0.01), and pulmonary arterial
compliance (þ0.39  0.83 ml/mm Hg; p < 0.01) were
also observed (Figure 2, Central Illustration, Table 4).
Reductions from baseline PVR of >10% were observed
in 14 patients (70%), and of those, 8 (40%) had re-
ductions of >20% (Figure 3). At 4 or 6 months, daily
activity was increased by 671  1,555 steps (p ¼ 0.04),
but no alteration was identified in cardiac output
(þ0.3  0.9 l/min; p ¼ NS), stroke volume index
(þ4.85  11.5 ml/min/m2; p ¼ 0.09), quality of life
(emPHasis-10 score 5.1  12.4; p ¼ 0.20), N-terminal
pro–brain natriuretic peptide (263.5  1,120 pg/ml;
p ¼ 0.2), systemic blood pressure (þ4.8 
24.4 mm Hg; p ¼ NS), and heart rate (þ0.05  8.2
beats/min; p ¼ NS) (Figures 2 and 4, Supplemental
Figure 1, Table 4). Hemodynamic and functional im-
provements were reflected in an increased number of
European Society of Cardiology low-risk indicators
achieved at 4- or 6-month follow-up (European Soci-
ety of Cardiology/French invasive risk score 0.4  0.6;
p < 0.001) (Figure 4, Central Illustration). Following
PDN, clinical worsening events occurred in 6 patients,
which were distributed throughout the follow-up
period (Figure 4).
DISCUSSION
This is the first study to examine the feasibility of
therapeutic intravascular ultrasound PDN and
describe early safety and clinical outcome indicators.
Following qualifying right heart catheterization, pa-
tients with PAH on a minimum of dual oral therapy
underwent immediate PDN. No procedure-related
serious adverse events were reported, and pulmo-
nary hemodynamic status, 6-min walk distance, and
daily activity improved at 4 or 6 months.
Patients were recruited from specialist pulmonary
hypertension centers, and the female predominance,
hemodynamic severity, and background therapy are
similar to those of large registries (21,22). The mean
age of 60 years, lengthy diagnosis-to-enrollment
duration, large number of patients on triple therapy,
and high proportion of connective tissue disease–
associated PAH also suggest that patients enrolled
were those established on guideline-directed therapy
with limited options for therapeutic escalation or
transplantation.
Ultrasound PDN was undertaken with no
procedure-related serious adverse events reported.
Of the 15 severe adverse events, 11 were disease-
related deterioration. At 12-month follow-up, clin-
ical worsening events had occurred in 6 of the 23
patients enrolled, a number typical for patients in
World Health Organization functional class III or IV
(23,24). As such, procedural feasibility and early
safety appear acceptable. Disease-specific and
diuretic therapy were maintained from baseline
to follow-up. At 4 or 6 months following PDN, a
TABLE 3 Serious Adverse Events and Adverse Events (All Patients Enrolled, N ¼ 23)
Event n Description
Serious adverse events
PAH hospitalization 11 Right ventricular failure/volume overload, syncope,
initiation of IV prostacyclin
Non-PAH hospitalization 3 Digoxin overdose, vasovagal episode, exacerbation of
lung disease
Death 1 Cardiac arrest
Adverse events
Anemia 2
Cardiac/PAH 32 Edema, chest pain, ECG changes, palpitations,
breathlessness, PAH progression/worsening
Infection 16 Urinary, respiratory, gastroenterological, dermatological,
dental
Pain 10 Pain during procedure, neck pain
Procedure related 7 Bleeding, hematoma, bruising, low saturation
Renal impairment 3
ECG ¼ electrocardiographic; IV ¼ intravenous; PAH ¼ pulmonary arterial hypertension.
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FIGURE 2 Pulmonary Vascular Hemodynamic Status at Baseline and 4 or 6 Months
(A) Pulmonary artery pressure (mean systolic pulmonary artery pressure: upper, þ95% confidence interval [CI]; mean of mean pulmonary artery pressure: white circles,
95% CI; mean diastolic pulmonary artery pressure: lower, 95% CI). (B) Pulmonary vascular resistance (PVR). (C) Right atrial pressure (RAP). (D) Cardiac output
(CO). (E) Pulmonary capillary wedge pressure (PCWP). (F) Systolic blood pressure (SBP). (G) Heart rate. (H) Pulmonary arterial compliance (PCa). (I) Stroke volume index
(SVI). n ¼ 20, mean  95% CI, Wilcoxon matched-pairs signed rank test or Student’s paired t-test as appropriate.
FIGURE 3 Change in PVR at 4 or 6 Months
Individual patient change in pulmonary vascular resistance (PVR) from baseline to 4 or 6 months following pulmonary artery denervation.
Rothman et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 1 3 , N O . 8 , 2 0 2 0
Ultrasound Pulmonary Artery Denervation: TROPHY1 A P R I L 2 7 , 2 0 2 0 : 9 8 9 – 9 9
994
94 dyn$s$cm5 reduction in PVR was observed, 6-min
walk distance was increased by 42 m, and systemic
blood pressure and heart rate were not altered. In
keeping with the observed reduction in PVR, both
right atrial pressure and pulmonary artery compli-
ance were improved (22). Although not statistically
significant, stroke volume index increased to a level
above the optimal absolute cutoff threshold associ-
ated with mortality or transplantation (38 ml/min/m2)
(22). In comparison with prior reports of PDN in pa-
tients with PAH (PADN-1 [First-in-Man Pulmonary
Artery Denervation for Treatment of Pulmonary
Artery Hypertension]) (16), patients enrolled in TRO-
PHY1 were older, with a longer time from diagnosis
and a high predominance of connective tissue dis-
ease, and were all established on guideline-directed
therapy. Consistent with PADN-1 (16), PDN improved
PVR in a manner driven primarily by a reduction in
pulmonary artery pressure. However, in TROPHY1,
no on-table reduction in pulmonary artery pressure
was apparent, and the magnitude of changes was
less marked. The observed reduction in PVR and
increase in 6-min walk distance achieved at 4 or
6 months in TROPHY1 are in line with hemodynamic
FIGURE 4 Functional and Clinical Outcomes
At 4 or 6 and 8 months following pulmonary artery denervation, distance walked on 6-min walk test (6MWT) (A) and daily activity (steps per
day) (B) were increased. Quality-of-life score (C) and N-terminal pro–brain natriuretic peptide (NT-proBNP) (D) were not changed. The
number of European Society of Cardiology low-risk criteria increased (E). Clinical worsening events were distributed throughout follow-up. In
A to E, n ¼ 20, mean  95% confidence interval, 1-way analysis of variance or chi-square test as appropriate. In F, n ¼ 23.
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CENTRAL ILLUSTRATION Pulmonary Vascular Hemodynamic and Functional Indicators at Baseline and Follow-Up
Intravascular ultrasound pulmonary artery denervation to treat pulmonary arterial hypertension
An open-label, early feasibility study of ultrasound pulmonary artery denervation in 23 patients with
pulmonary arterial hypertension established on guideline-directed medical therapy
0
10
20
p = 0.008
p = 0.02
30
40
50
60
70
80
90
100
BL 4/6M
P
u
lm
o
n
a
ry
 A
rt
e
ry
 P
re
ss
u
re
 (
m
m
 H
g
)
p = 0.006
A
0
400
500
600
700
800
900
p = 0.001
BL 4/6m
P
V
R
 (
d
y
n
·s
·c
m
5
)
B
D
p = 0.007
0
6
8
10
12
14
BL 4/6m
R
A
P
 (
m
m
 H
g
)
C
Number of Low Risk Criteria Met
3 2 1 0
0
250
300
350
400
450
p = 0.03
p = 0.03
p = 0.27
BL 1m 4/6m 8m
6
M
W
T
 (
m
)
0
50
100
BL 4/6m
P
a
ti
e
n
ts
 (
%
)
p < 0.001
20
60
20 20
40
25
15
E
Rothman, A.M.K. et al. J Am Coll Cardiol Intv. 2020;13(8):989–99.
(A) Pulmonary artery pressure (mean systolic pulmonary artery pressure: upper, þ95% confidence interval [CI]; mean of mean pulmonary artery pressure: white
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square test as appropriate.
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outcomes of approved drug therapies and compare
favorably with a minimally important clinical dif-
ference in 6-min walk distance of 33 m (25). The
observed increase in daily activity and improved
clinical risk score provide further indication of po-
tential benefit on a background of guideline-directed
medical therapy.
Markers of neurohormonal activity are increased in
patients with PAH and are associated with adverse
clinical events (1,2). The pulmonary vasculature is
highly innervated, releasing and metabolizing >40%
of circulating catecholamines (3). The pulmonary
(nerve) plexus is predominantly sympathetic and is
innervated by fibers from the spinal ganglions (sym-
pathetic) and vagus nerve (parasympathetic) (15).
Baroreceptor structures have been described at the
pulmonary artery bifurcation (26), and balloon
distention of the main pulmonary artery increases
pulmonary artery pressure and PVR (27). These acute
changes are abrogated by surgical denervation and
chemical sympathectomy implicating sympathetic
nerves in the reflex (27). Furthermore, sympathetic
inhibition, through cervical ganglion block, reduces
pulmonary artery pressure in the context of acute
pulmonary embolism (28). In experimental models,
denervation of the pulmonary artery induces persis-
tent structural and functional changes within associ-
ated nerves and improves hemodynamic changes
driven by balloon distention (29), vasoconstriction
(13,15), and small-vessel remodeling (14). The
elevated PVR apparent in patients with PAH is driven
by small-vessel remodeling but also leads to
increased pulmonary artery pressure. The present
study demonstrates improvements in pulmonary
vascular hemodynamic status and functional capacity
4 or 6 months following PDN. In contrast to prior re-
ports of radiofrequency PDN, no acute reduction in
pulmonary artery pressure was observed with ultra-
sound PDN in this study, suggesting a potential
remodeling effect.
The health-economic cost of PAH-specific therapy
and clinical deterioration is high (30); dual oral ther-
apy is priced at $30,000 to $50,000 per year per pa-
tient and triple therapy at $50,000 to $160,000 per
patient per year (31,32). As such, a single, or repeated-
interval, catheterization laboratory–based procedure
may provide an alternative to therapeutic escalation
or an addition to combination therapy.
STUDY STRENGTHS AND LIMITATIONS. The study
was open label, with no placebo arm. Patients and
responsible physicians were not blinded, and the
potential effect of placebo cannot be quantified.
Patients were recruited from specialist centers at
which serial walk testing was part of routine care,
thereby reducing potential training and learning ef-
fects. To minimize potential bias, hemodynamic
studies were assessed by an independent core labo-
ratory, blinded to subject and sequence, and data
were analyzed by an independent statistician in
accordance with the pre-specified analysis plan.
Additionally, for this procedure, there is no immedi-
ate feedback to the operator to indicate success-
ful denervation.
CONCLUSIONS
Intravascular ultrasound PDN was feasible, reduced
PVR, and increased 6-min walk distance and daily
activity in patients with PAH treated with dual oral or
triple therapy. Further studies are required to eval-
uate the efficacy, durability, safety, and long-term
clinical impact of PDN in patients with pulmonary
hypertension of various forms.
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TABLE 4 Hemodynamics at Baseline and 4- or 6-Month Follow-Up (N ¼ 20)
Baseline 4 or 6 Months p Value
Right atrial pressure (mm Hg) 10.7 (8.1–13.3) 8.3 (6.1–10.5) 0.008
Pulmonary artery pressure (mm Hg)
Systolic 80.7 (68.8–92.5) 74.3 (63.1–85.4) 0.02
Mean 49.3 (42.5–56.1) 44.2 (37.4–51.0) 0.006
Diastolic 32.1 (27.3–36.8) 27.7 (22.3–33.1) 0.007
Pulmonary arterial wedge pressure (mm Hg) 13.4 (11.2–15.6) 12.9 (10.6–15.3) 0.63
Cardiac output (l/min) 4.9 (4.3–5.6) 5.2 (4.4–6.1) 0.41
Pulmonary vascular resistance (dyn$s$cm5) 670 (479–861) 576 (373–779) 0.001
Systemic blood pressure (mm Hg)
Systolic 120 (113.0–126.9) 124.1 (112.4–135.7) 0.72
Diastolic 75.4 (69.7–81.1) 75.7 (69.5–81.9) 0.74
Heart rate (beats/min) 78.4 (73.7–83.2) 78.1 (72.4–83.8) 0.87
Values are mean (95% confidence interval).
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PERSPECTIVES
WHAT IS KNOWN? Early studies have suggested that
PDN reduces PVR in patients with PAH.
WHAT IS NEW? In this multicenter early feasibility
study, ultrasound PDN was performed without
procedure-related adverse events and was associated
with a reduction PVR and increases in 6-min walk distance
and daily activity in patients with PAH on a minimum of
dual oral therapy.
WHAT IS NEXT? Further studies are required to eval-
uate the efficacy, durability, safety, and long-term clinical
impact of PDN in patients with pulmonary hypertension
of various forms.
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